Creative Biolabs’ one-stop microfluidic platform accelerates biomedical breakthroughs by streamlining chip innovation for faster, scalable, and physiologically relevant discoveries.
SHIRLEY, NY, April 25, 2026 /24-7PressRelease/ — Current research on microfluidic solutions is rapidly advancing, with droplet-based systems, wearable integration, and protein interaction studies driving biomedical innovation and clinical translation. Creative Biolabs, a global leader in biotechnology contract research, today announced the expansion of its one-stop microfluidic solutions. By integrating advanced neuron-on-a-chip models and cell separation/sorting chip development into a unified service, the company is providing researchers with a comprehensive toolkit to accelerate drug discovery, disease modeling, and precision diagnostics.
From Conventional Methods to Microfluidic Innovation
Traditional cell culture and separation techniques often consume large amounts of reagents, require bulky equipment, and fail to replicate the complexity of human biology. Creative Biolabs’ microfluidic platform addresses these limitations by miniaturizing and automating biological processes, enabling high-throughput analysis and physiologically relevant models.
“Our one-stop microfluidic solutions are designed to bridge the gap between laboratory assays and clinical realities,” said a senior scientist at Creative Biolabs. “By integrating neuron-on-a-chip and cell sorting technologies, we empower researchers to achieve reproducible, scalable, and clinically meaningful results.”
Key Platform Capabilities
Neuron-on-a-Chip Models
• Dual-chamber designs for controlled axon growth
• Integration with electrophysiological monitoring for real-time neural activity
• Applications in neurodegenerative disease research, drug resistance studies, and neural network analysis
Cell Separation & Sorting Chips
• Gentle isolation based on intrinsic cell properties such as size, density, and electrical characteristics
• High-purity (_95%) separation while preserving cell viability
• Applications in oncology (CTC isolation), immunotherapy, and stem cell enrichment
Platform Advantages
• End-to-end support from design to validation
• Reduced reagent consumption and faster reaction times
• High-throughput, scalable, and reproducible results
Technical Insight: Microfluidics FAQ
To assist researchers in navigating these emerging technologies, Creative Biolabs has synthesized key technical clarifications:
Q: How do microfluidic chips improve drug screening?
A: They allow real-time monitoring of cellular responses in physiologically relevant environments, reducing false positives.
Q: Can microfluidics replace traditional flow cytometry?
A: Yes, chips provide portable, cost-effective alternatives with high purity and recovery rates.
Q: What is the scalability of neuron-on-a-chip models?
A: These platforms are designed for reproducibility, enabling high-throughput studies across multiple disease models.
Ready to advance your research? Discover neuron-on-a-chip technologies and speak with specialists at https://microfluidics.creative-biolabs.com/.
About Creative Biolabs
Creative Biolabs is a contract research organization specializing in microfluidics, organ-on-a-chip, and advanced biomedical solutions. With a team of Ph.D.-level scientists and over a decade of expertise, the company delivers customized platforms that accelerate global research in oncology, neuroscience, and regenerative medicine.
—
For the original version of this press release, please visit 24-7PressRelease.com here
Legal Disclaimer: This article was provided by an independent third-party content provider. Kyrion Media makes no warranties or representations in connection with it. All information is provided “as is” without warranty of any kind. This content may not have been reviewed by our editorial staff and is published automatically. The views expressed in this article are those of the author and do not necessarily reflect the views of Kyrion Media. All trademarks are the property of their respective owners. If you are affiliated with this article and would like it removed, please contact retract@kyrionmedia.com.
